Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750411 · ClinicalTrials.gov registry record
Severe Asthma Research Program - Wake Forest University
A clinical trial, sponsored by Wake Forest University.
- Completed
- Registry status
- 87
- Enrollment target
NCT01750411: Completed study, sponsored by Wake Forest University.
NCT01750411 is a clinical trial that has completed, run by Wake Forest University. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01750411 has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- 87 participants
- Enrollment target
Study Summary
The mission of SARP is to improve the understanding of severe asthma through the integrated study of the effect of genetics on the clinical and biological features of asthma and to investigate how these change over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.
Primary Outcome
Pulmonary function test results include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-12 |
| Est. Completion | 2021-01-15 |
What the finished NCT01750411 record still lists
NCT01750411 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01750411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01750411 about?
NCT01750411 is a clinical study titled "Severe Asthma Research Program - Wake Forest University". The mission of SARP is to improve the understanding of severe asthma through the integrated study of the effect of genetics on the clinical and biological features of asthma and to investigate how these change over time. The ultimate goal of these efforts is to promote better treatments for severe a...
What is the current status of trial NCT01750411?
This trial is currently completed. The enrollment target is 87 participants. The study started on 2012-12. Estimated completion is 2021-01-15.
Who is sponsoring clinical trial NCT01750411?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia